Verastem Oncology Initiates Phase 1/2 Trial in China for KRAS G12D Inhibitor GFH375/VS-7375 with GenFleet

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the first patient has been dosed in a Phase 1/2 trial in China, conducted by GenFleet Therapeutics, evaluating GFH375/VS-7375, a KRAS…

Read MoreVerastem Oncology Initiates Phase 1/2 Trial in China for KRAS G12D Inhibitor GFH375/VS-7375 with GenFleet

Endoron Medical Raises $10M to Accelerate Validation of AAA EndoStapling Solution

Endoron Medical, a pioneering medtech firm specializing in innovative endograft stapling solutions for abdominal aortic aneurysms (AAA), has successfully closed a $10 million Series A funding round. Sofinnova Partners led the round, with substantial contributions from the European Innovation Council…

Read MoreEndoron Medical Raises $10M to Accelerate Validation of AAA EndoStapling Solution